The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy
Open accessAbstract
PURPOSE: Approximately 30%-40% of patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) infused with CD19-targeted chimeric antigen receptor (CAR) T cells achieve durable responses. Consensus guidelines suggest avoiding bendamustine before apheresis, but specific data in this setting are lacking. We report distinct outcomes after CAR T-cell therapy according to previous bendamustine exposure. METHODS: The study included CAR T-cell recipients from seven European sites. Safety, efficacy, and CAR T-cell expansion kinetics were analyzed according to preapheresis bendamustine exposure. Additional studies on the impact of the washout period and bendamustine dose were performed. Inverse probability treatment weighting (IPTW) and propensity score matching (PSM) analyses were carried out for all efficacy comparisons between bendamustine-exposed and bendamustine-naïve patients. RESULTS: The study included 439 patients with R/R LBCL infused with CD19-targeted commercial CAR T cells, of whom 80 had received bendamustine before apheresis. Exposed patients had significantly lower CD3 + cells and platelets at apheresis. These patients had a lower overall response rate (ORR, 53% v 72%; P < .01), a shorter progression-free survival (PFS, 3.1 v 6.2 months; P = .04), and overall survival (OS, 10.3 v 23.5 months; P = .01) in comparison with the bendamustine-naïve group. Following adjustment methods for baseline variables, these differences were mitigated. Focusing on the impact of bendamustine washout before apheresis, those with recent (<9 months) exposure (N = 42) displayed a lower ORR (40% v 72%; P < .01), shorter PFS (1.3 v 6.2 months; P < .01), and OS (4.6 v 23.5 months; P < .01) in comparison with bendamustine-naïve patients. These differences remained significant after IPTW and PSM analysis. Conversely, the cumulative dose of bendamustine before apheresis did not affect CAR-T efficacy outcomes. CONCLUSION: Recent bendamustine exposure before apheresis was associated with negative treatment outcomes after CD19-targeted CAR T-cell therapy and should be therefore avoided in CAR T-cell candidates.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“were higher for participants treated with epcoritamab plus R² due to overlapping toxicities in line with previous reports of T-cell engaging immunotherapies.”
In the citing paper
“early-phase trials consistently reported complete response rates of more than 65%. 29-33”
Citations
Cites
Austin, P. C. (2011) · Multivariate Behavioral Research · doi:10.1080/00273171.2011.568786 · Cited by 12,242
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Austin, P. C., & Stuart, E. A. (2015) · Statistics in Medicine · doi:10.1002/sim.6607 · Cited by 4,495
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Abramson, J. S., Palomba, M. L., Gordon, L. I., Lunning, M. A., Wang, M., Arnason, J., Mehta, A., Purev, E., Maloney, D. G., Andreadis, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31366-0 · Cited by 2,430 · cited 2×
“%] and tisa-cel in 185 [42”
BackgroundLocke, F. L., Ghobadi, A., Jacobson, C. A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30864-7 · Cited by 2,286
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Crump, M., Neelapu, S. S., Farooq, U., Van Den Neste, E., Kuruvilla, J., Westin, J., Link, B. K., Hay, A., Cerhan, J. R., Zhu, L., et al. (2017) · Blood · doi:10.1182/blood-2017-03-769620 · Cited by 1,703
Rummel, M. J., Niederle, N., Maschmeyer, G., Banat, G. A., von Grünhagen, U., Losem, C., Kofahl-Krause, D., Heil, G., Welslau, M., Balser, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61763-2 · Cited by 1,510
Nastoupil, L. J., Jain, M. D., Feng, L., Spiegel, J. Y., Ghobadi, A., Lin, Y., Dahiya, S., Lunning, M., Lekakis, L., Reagan, P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02104 · Cited by 801
Research works printed but not linked: 3
- Bethge WA, 2022, Blood, 140, 349
- Neelapu SS, 2023, Blood, 141, 2307
- van Buuren S, 2011, J Stat Softw, 45, 1
Cited by
Falchi, L., Nijland, M., Huang, H., Linton, K. M., Seymour, J. F., Tao, R., Kwiatek, M., Costa, A., Vassilakopoulos, T. P., Greil, R., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02360-8 · Cited by 41
Metadata
- Authors
- Iacoboni, G., Navarro, V., Martín-López, A. Á., Rejeski, K., Kwon, M., Jalowiec, K. A., Amat, P., Reguera-Ortega, J. L., Gallur, L., Blumenberg, V., Gutiérrez-Herrero, S., Roddie, C., Benzaquén, A., Delgado-Serrano, J., Sánchez-Salinas, M. A., Bailén, R., Carpio, C., López-Corral, L., Hernani, R., Bastos, M., O'Reilly, M., Martín-Martín, L., Subklewe, M., & Barba, P.
- Affiliations
- Universitat Autònoma de Barcelona (ES)
- Oncology Data Science (ODySey) Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
- Hematology Department, Hospital Clínico Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, Spain
- LMU Klinikum (DE)
- Hospital General Universitario Gregorio Marañón (ES)
- University Hospital of Bern (CH)
- Hospital Clínico Universitario de Valencia (ES)
- Hematology Department, Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC, Universidad de Sevilla, Sevilla, Spain
- Universidad de Salamanca (ES)
- University College London (GB)
- Haematology Department, Hospital Clínico Universitario, Valencia, Spain
- Department of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
- Cancer Research Centre (IBMCC, USAL-CSIC), Institute for Biomedical Research of Salamanca (IBSAL) and Department of Medicine and Cytometry Service (NUCLEUS Research Support Platform), University of Salamanca (USAL), Salamanca, Spain
- ORCID
- Iacoboni, Gloria
- Navarro, Víctor
- Rejeski, Kai
- Kwon, Mi
- Jalowiec, Katarzyna Aleksandra
- Amat, Paula
- Gallur, Laura
- Blumenberg, Viktoria
- Gutiérrez-Herrero, Sara
- Roddie, Claire
- Benzaquén, Ana
- Sánchez-Salinas, Mario Andrés
- Bailén, Rebeca
- Carpio, Cecilia
- Hernani, Rafael
- Bastos, Mariana
- O'Reilly, Maeve
- Martín-Martín, Lourdes
- Subklewe, Marion
- Barba, Pere
- Venue
- Journal of Clinical Oncology
- Published
- 2024-01-10
- Volume
- 42
- Issue
- 2
- Pages
- 205-217
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W4387900511
- Cited by
- 143
- References
- 44
- Citations by year
- 2026: 40 · 2025: 53 · 2024: 41
- FWCI
- 17.44
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- Open Access CRIS of the University of Bern
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- bendamustine, large B-cell lymphoma, relapsed/refractory lymphoma, CAR T-cell therapy, CD19 CAR T cells, apheresis, overall response rate, progression-free survival, overall survival, drug-drug interactions, platelet count
- MeSH terms
- Bendamustine Hydrochloride, Receptors, Chimeric Antigen, Blood Component Removal, Humans, Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse, Antigens, CD19, Cell- and Tissue-Based Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy. https://app.cochat.ai/papers/10.1200/jco.23.01097
- The paper
- Iacoboni, G., Navarro, V., Martín-López, A. Á., Rejeski, K., Kwon, M., Jalowiec, K. A., Amat, P., Reguera-Ortega, J. L., Gallur, L., Blumenberg, V., Gutiérrez-Herrero, S., Roddie, C., Benzaquén, A., Delgado-Serrano, J., Sánchez-Salinas, M. A., Bailén, R., Carpio, C., López-Corral, L., Hernani, R., . . . Barba, P. (2024). Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.01097
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
